Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Perhaps the blue touch paper has been lit?
Exactly Lazarus 2, it's that research that keeps me believing in Sareum and many thanks to those who share such.
@ Celtic no offence and I appreciate your support of this bb, but, was there any need to bring FG into this thread - gives him an opportunity to work his agenda!
GLA
Morning Celtic - that's just how business works sometimes. We just have to wait and see.
Exactly ...Lazarus. great research and so nice to have all the septic people nearly out of here. See funny guy still here, like a bad fart, but the data released soon going to act like a deodorant to neutralise him and his shorting bricks
The research on this board is second to none and is a major confidence boost to those of us believing in the future of Sareum.
Stars and ducks are aligning I feel and, irrespective of market shenanigans, true value will eventually be established. Thank you all for sharing.
SRA737 for prostate cancer
“SRA737 exhibiting remarkable single agent anticancer activity”
Exactly right. The average licencing deal for platform and discovery candidates in 2023 was $47 million and $55 Million respectively. The $63 million KYM licencing deal for its P1 candidate was at a slight premium to that.
* The average Phase 2 upfront licencing payment in our sector was much higher at $310 million in 2023.
* In the not too distant future we could be waking up to an RNS announcing a licencing deal for SDC-1801. Why would anyone want to miss out on that opportunity?
See the link to the full report on up front payments for licencing deals in our sector in 2023 below...
Good luck, Brighty
https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpmorgan-dec-2023-biopharma-licensing-and-venture-report.pdf
Apologies if already posted
https://www.researchgate.net/publication/377699214_Synthetic_lethal_combination_of_CHK1_and_WEE1_inhibition_for_treatment_of_castration-resistant_prostate_cancer
Last year AstraZeneca entered in to an agreement with KYM Biosciences for its Phase I clinical candidate CMG901. AZ paid an upfront payment of $63m and agreed additional milestone development and sales-related payments of up to $1.1bn.
Beware of the devious or ignorant on this chat forum who have no comprehension of the significant upside big pharma will pay for a new P1 candidate such as SDC-1801.
Good morning Bobbler,
Excellent post and an important link.
It maybe worthwhile noting thst Acrivon has been designated fast track in endometrial and breast cancer ( 2023). Prexasertib and IV admistered chk1 2 inhibitor.
https://www.cancernetwork.com/view/fda-grants-ftd-to-prexasertib-in-ovarian-endometrial-cancers
Future is very bright for Chk1 inhibitors in combo therapy. On its own it is effective in what it us designed to do but needs assistance from DNA damaging agents eg gemcitabine.
Regards
Great research thank you. Am sure this company makes a asthma drug called spiriva as well . Thank you . Big German pharmaceutical....a beast you would say
Amazing research and a very big thank you. Add this drug (737) to 1801 and it goes some way to show Sareum have assets that can really make a difference to people’s lives. Let alone the company. Well done indeed.
HBD ref SRA737, I think the partner could possibly be Boehringer Ingelheim US subsidiary, technically this is a private US based company, ultimately owned by the parent in Germany. Boehringer Ingelheim Inc will have issued shares (private) and could therefore offer them as part of the deal.
Boehringer Ingelheim Collaborate extensively with Cancer Research Technology (trading as Cancer Research Horizons).
Full Disclosure of interactions with industry:
Sometimes, through Cancer Research Technology Limited, Cancer Research UK will receive shares rather than financial payments when research partnerships are created. Cancer Research UK does not usually apply a market value to such shareholdings but some information concerning these shareholdings can be found in Cancer Research Technology Limited’s statutory accounts filed at Companies House.
Boehringer are significantly involved in combo trials of xentuzumab with other drugs.
https://pubmed.ncbi.nlm.nih.gov/37308971/
Researchers based at the University of Oxford have discovered a way to boost the effectiveness of a new type of drug, called xentuzumab, which is currently being tested for breast cancer.
They found that xentuzumab was most effective when combined with drugs MK-8776 and SRA737, which block a protein called CHK1, and AZD1775 that blocks WEE1 protein.
https://breastcancernow.org/about-us/research-news/researchers-discover-way-boost-effectiveness-new-breast-cancer-drug/
Hi hot. Selling on? Is that good for us? Might we mot get the full value?
Hi Lsesar - having completed P2 trials in combo, the BoD may have presumed 737 was at a point in its development that would attract larger upfront payments upon further licensing. Seems perfectly reasonable to me based on what I've read regarding deals for potentially P3-ready compounds. So who here expected a near carbon-copy of the Sierra deal?
Celtic - it's near enough 4mths since the license was announced and there isn't even a hint of who has it in any corner of the internet. For all we know it's been renamed and is currently undergoing preclinical research in combination with other drugs prior to trials in humans.
I keep looking on the US clinical trials website for any newly registered trials mentioning chk1 or anything that could be linked to 737 - nothing to report so far.
We can't even say for sure if our own BoD know who has it. You'd have thought the US firm would announce the deal in a 'look at us! see what we're doing now!' kind of way. I can only hope bigger games are being played behind the scenes and we'll all be pleasantly surprised when we know what's really going on.
Although Potnak suggests it might be with a small company looking to do a bit of work on it before selling it on (which is plausible), I'd be surprised if the CPF picked a small company over a larger pharma to progress 737 (assuming large pharma were interested).
In a nutshell, I'm stumped.
I just hope any negotiations are done with proper advisors who have a excellent track record. The bod have proven to me that they can’t do any licensing/ partner deals alone.
Hbd - I think the reality was that the bod were reliant on a buoyant share price and fully intended to drawn down every penny of the RF funding - we all know how that panned out. I can’t see how they could think that 737 would provide enough funding. I think it is more naivety and poor management perhaps?
The problem with partnerships and licensing deal is that I see this becoming a long drawn out trip to achieve real gains . We already have a deal with 10s of millions in milestone payments but here we are languishing . Honestly the bod need to take a reality check and do the “right” deal. Maybe given that most of us hold more shares than they do, they are not so driven?
Thanks hot. I also think same as you, they know that it was potential combo blockbuster from all the data and they would make sense . Dont understand why these companies hide their details from us...
CHK 1 has shown great data on combo in humans so we know it works and a umet market there with anogenital and other cancers.....
Hopefully new pharmaceutical that has taken will show their trie colours and take it forward.... hopefully we know by November I think? Any views appreciated ta
Conz/Dorset - at the time the BoD maybe knew a 737 license was in the closing stages and they probably thought there'd be an upfront payment large enough to cover our needs so RF was just a 'short-term payday loan' that turned out to be ill-advised and/or poorly chosen. Suddenly it went from we only need a a few quid to tide us over until the end of the month to oh crikey, we're now tied to a chair in a deserted warehouse and our kneecaps are soon to be history.
Luckily, enough shareholders heard the screaming and burst in to save the day.
I also think how can people so smart get it so wrong. It's not that this type of finance does not have form and past bad outcomes could have predicted the mess we ended up in especially with the jackals of AIM looking to feast on the wounded beast for short term gain. I recall the board making a specific point that its was flexible and only funds that were required would be drawn down which gives your theory legs. But then I think that people, no matter how smart need to have a business rather than a scientific brain/experience to navigate such treacherous waters and this lack of appointment was the root cause.
Just in my view
Hi Celtic - any intellectual property Sierra was able to develop whilst 737 was licensed to them should be handed over to the CRT Pioneer Fund as they are the owners of 737 (we are only financial beneficiaries if there's a commercial license). This doesn't stop anyone from patenting a novel use of the compound e.g. the Celtic007 Pharmaceuticals & Dangerous Toy Company Ltd doesn't own the rights to 737 but you could patent a use which if approved means someone would have to pay you a fee if their use infringes your patent.
If you look at another patent (see below) and click on the 'show all events' filter in the right-hand column, you'll see an entry dated 5/2/24 that says the patent is assigned to CRT Pioneer Fund.
https://patents.google.com/patent/US20210077499A1/en?oq=US20210077499A1
It's possible all IP has been handed over by Sierra but the admin side is yet to filter through to all the patents. I still think our mystery licensee is Sierra (again) as they have so much work in the compound & patents.
Just my thoughts on this one Potnak.
I would suggest that it may very well be that 1802 has a higher selectivity over Jak3 than 1801
As far as l can remember there was a Jak 3 inhibitor Ruxolitinib ( not sure if spelled correctly)
that was used and approved in some haematology cancers some years ago. I also am of the belief that it was to be approved for T ALL cancer just a few years back.
The point here is that whilst Jak3 may well be adept at cancers it does knacker the immune system leading to increased risk of infections.
Jak3 can only pair with Jak1.
I would suggest also along with T ALL cancer it may prove effective in colon or bowel cancer.
Now, UC and CD have a high tenancy to lead to colon or bowel cancer.
Such is the close link here between the 2 that dependant on severity 1802 may prove to have greater efficacy in UC and CD.
I may be off my nut, but is just my way of thinking on this.
Regards
Surely when sierra handed back then all patents went back to us? What use is them having a patent but not that molecule? Thanks